H
Henning T. Mouridsen
Researcher at University of Copenhagen
Publications - 121
Citations - 16119
Henning T. Mouridsen is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 52, co-authored 120 publications receiving 15464 citations. Previous affiliations of Henning T. Mouridsen include Copenhagen University Hospital & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
Marie Overgaard,Per S. Hansen,Jens Overgaard,Carsten Rose,Martin Andersson,Flemming W. Bach,Mogens Kjaer,Carl C. Gadeberg,Henning T. Mouridsen,Maj-Britt Jensen,Karin Zedeler +10 more
TL;DR: Multivariate analysis demonstrated that irradiation after mastectomy significantly improved disease-free survival and overall survival, irrespective of tumor size, the number of positive nodes, or the histopathological grade.
Journal ArticleDOI
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
Beat Thürlimann,Aparna Keshaviah,Alan S. Coates,Henning T. Mouridsen,Louis Mauriac,John F. Forbes,Robert Paridaens,Monica Castiglione-Gertsch,Richard D. Gelber,Manuela Rabaglio,Ian E. Smith,Andrew M Wardley,Karen N. Price,Aron Goldhirsch +13 more
TL;DR: In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites.
Journal ArticleDOI
Postoperative radiotherapy in high-risk postmenopausal breast- cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
Marie Overgaard,Maj-Britt Jensen,Jens Overgaard,Per S. Hansen,Carsten Rose,Martin Andersson,Claus Kamby,Mogens Kjaer,Carl C. Gadeberg,Birgitte Bruun Rasmussen,Mogens Blichert-Toft,Henning T. Mouridsen +11 more
TL;DR: Postoperative radiotherapy decreased the risk of locoregional recurrence and was associated with improved survival in high-risk postmenopausal breast-cancer patients after mastectomy and limited axillary dissection, with 1 year of adjuvant tamoxifen treatment.
Journal ArticleDOI
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Ramon Perez-Carrion,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Fritz Jänicke,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,Mercedes Lassus,J. Arnold Verbeek,Beatrix Staffler,H. A. Chaudri-Ross,Margaret Dugan +20 more
TL;DR: Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate, and its results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Journal ArticleDOI
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
Alan S. Coates,Aparna Keshaviah,Beat Thürlimann,Henning T. Mouridsen,Louis Mauriac,John F. Forbes,Robert Paridaens,Monica Castiglione-Gertsch,Richard D. Gelber,Marco Colleoni,István Láng,Lucia Del Mastro,Ian E. Smith,Jacquie Chirgwin,J.M. Nogaret,Tadeusz Pienkowski,Andrew M Wardley,Erik Jakobsen,Karen N. Price,Aron Goldhirsch +19 more
TL;DR: The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.